The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Targeting ALK: Precision Medicine Takes on Drug Resistance
Open accessAbstract
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, including non–small cell lung cancer. However, the clinical benefit of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance. Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic. In this review, we summarize the current successes and challenges of targeting ALK. Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance. This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms. Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome. Cancer Discov; 7(2); 137–55. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 1×
“Indeed, no responses were seen among 6 patients with ALK-positive NSCLC treated with checkpoint inhibitors in a small retrospective analysis (152), and in large randomized studies of previously treated NSCLC, subgroup analyses demonstrated no survival benefit to checkpoint inhibitors over chemotherapy in never-smokers…”
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Self-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Self-citationCrizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · cited 3×
“Soon thereafter, two phase III trials showed that crizotinib was superior to first- and second-line cytotoxic chemotherapy in advanced ALK-rearranged NSCLC (3, 4).”
BackgroundSelf-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870
Self-citationThress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Self-citationLanger, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,309
Self-citationGainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Self-citationActivation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,189
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo-Jack, I., Gadgeel, S., Schultz, K., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,148
Self-citationGenomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K. L., Maher, C. A., Fulton, R., Fulton, L., Wallis, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.024 · Cited by 1,146
Gomez, D. R., Blumenschein, G. R., Lee, J. J., Hernandez, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30532-0 · Cited by 1,086
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,063
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2291 · Cited by 882
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D'Adamo, D. R., Hornick, J. L., Dal Cin, P., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2673 · Cited by 869
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862 · cited 2×
“Although pharmacologic properties of TKIs can also limit ALK TKI efficacy, particularly for CNS disease, these issues are beyond the scope of this review and have been discussed elsewhere (68).”
BackgroundOxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7162 · Cited by 850
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A. S., Michellys, P.-Y., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 840
Self-citationBalak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 824
Self-citationZou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B., & Yamamoto, T. (1997) · Oncogene · doi:10.1038/sj.onc.1200849 · Cited by 726
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
Lawrence, B., Perez-Atayde, A., Hibbard, M. K., Rubin, B. P., Dal Cin, P., Pinkus, J. L., Pinkus, G. S., Xiao, S., Yi, E. S., Fletcher, C. D. M., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64550-6 · Cited by 714
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
Self-citationGadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A. A., West, H. L., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 698
Self-citationWeickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11815 · Cited by 648
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7377 · Cited by 647 · cited 1×
“Conceptually, this lineage change may contribute to ALK TKI resistance in a manner similar to EGFR TKI resistance, which has been associated with the acquisition of RB loss and genetic or epigenetic features of classic SCLC (103).”
BackgroundMechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Hallberg, B., & Palmer, R. H. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3580 · Cited by 645
Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citationCH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N., & Aoki, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.004 · Cited by 636
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, J. P., Du, J., Okuda, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1340 · Cited by 597
Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 594
Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583 · cited 4×
“The difference in spectrum of resistance mutations may be attributable to the genetic mechanism of oncogene activation (i.e., gene rearrangements involving ALK or ABL , versus activating point mutations within the EGFR kinase domain) and/or the mode of TKI binding (i.e., to the inactive kinase conformation for imatini…”
BackgroundInfluentialDiverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581
Ou, S.-H. I., Ahn, J. S., De Petris, L., Govindan, R., Yang, J. C.-H., Hughes, B., Lena, H., Moro-Sibilot, D., Bearz, A., Ramirez, S. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 580
Katayama, R., Khan, T. M., Benes, C., Lifshits, E., Ebi, H., Rivera, V. M., Shakespeare, W. C., Iafrate, A. J., Engelman, J. A., & Shaw, A. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019559108 · Cited by 542
Self-citationA mouse model for EML4-ALK -positive lung cancer
Soda, M., Takada, S., Takeuchi, K., Choi, Y. L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., Yamashita, Y., Ishikawa, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805381105 · Cited by 512
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503 · cited 1×
“The aim of targeting mechanisms of TKI resistance is two-fold: (i) effectively treat the relapsed disease by overcoming the dominant resistance mechanism and (ii) enhance the depth and duration of tumor response up front by preventing the emergence of resistance (60).”
BackgroundNivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Gettinger, S., Rizvi, N. A., Chow, L. Q., Borghaei, H., Brahmer, J., Ready, N., Gerber, D. E., Shepherd, F. A., Antonia, S., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9929 · Cited by 501
Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3224 · Cited by 499 · cited 1×
“Indeed, in the case of EGFR-mutant lung cancers, primary resistance can arise due to a preexisting T790M gatekeeper mutation (109, 110).”
BackgroundResensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Shaw, A. T., Friboulet, L., Leshchiner, I., Gainor, J. F., Bergqvist, S., Brooun, A., Burke, B. J., Deng, Y.-L., Liu, W., Dardaei, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508887 · Cited by 484
Self-citationKim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471
Self-citationZou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., Tang, R. W., Wang, H., Tsaparikos, K., Wang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.010 · Cited by 471
Self-citationALK in Lung Cancer: Past, Present, and Future
Shaw, A. T., & Engelman, J. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5353 · Cited by 461
Self-citationInflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
Lovly, C. M., Gupta, A., Lipson, D., Otto, G., Brennan, T., Chung, C. T., Borinstein, S. C., Ross, J. S., Stephens, P. J., Miller, V. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0377 · Cited by 455
Rizvi, N. A., Hellmann, M. D., Brahmer, J. R., Juergens, R. A., Borghaei, H., Gettinger, S., Chow, L. Q., Gerber, D. E., Laurie, S. A., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9861 · Cited by 445
Douillard, J.-Y., Ostoros, G., Cobo, M., Ciuleanu, T., McCormack, R., Webster, A., & Milenkova, T. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.721 · Cited by 412
Huang, W.-S., Liu, S., Zou, D., Thomas, M., Wang, Y., Zhou, T., Romero, J., Kohlmann, A., Li, F., Qi, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00306 · Cited by 412
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., Mussolin, B., Kwak, E. L., Buscarino, M., Lazzari, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1283 · Cited by 405
Evolutionary Determinants of Cancer
Greaves, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0439 · Cited by 395
Fusion of the ALK Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic Tumor
Bridge, J. A., Kanamori, M., Ma, Z., Pickering, D., Hill, D. A., Lydiatt, W., Lui, M. Y., Colleoni, G. W. B., Antonescu, C. R., Ladanyi, M., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61711-7 · Cited by 359
Gettinger, S. N., Bazhenova, L. A., Langer, C. J., Salgia, R., Gold, K. A., Rosell, R., Shaw, A. T., Weiss, G. J., Tugnait, M., Narasimhan, N. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30392-8 · Cited by 352
Self-citationSasaki, T., Okuda, K., Zheng, W., Butrynski, J., Capelletti, M., Wang, L., Gray, N. S., Wilner, K., Christensen, J. G., Demetri, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 335
Zhang, S., Anjum, R., Squillace, R., Nadworny, S., Zhou, T., Keats, J., Ning, Y., Wardwell, S. D., Miller, D., Song, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0569 · Cited by 330
Ardini, E., Menichincheri, M., Banfi, P., Bosotti, R., De Ponti, C., Pulci, R., Ballinari, D., Ciomei, M., Texido, G., Degrassi, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0758 · Cited by 321
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
Medico, E., Russo, M., Picco, G., Cancelliere, C., Valtorta, E., Corti, G., Buscarino, M., Isella, C., Lamba, S., Martinoglio, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8002 · Cited by 302
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers
Lin, E., Li, L., Guan, Y., Soriano, R., Rivers, C. S., Mohan, S., Pandita, A., Tang, J., & Modrusan, Z. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0522 · Cited by 302
Menichincheri, M., Ardini, E., Magnaghi, P., Avanzi, N., Banfi, P., Bossi, R., Buffa, L., Canevari, G., Ceriani, L., Colombo, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00064 · Cited by 299
Cools, J., Włodarska, I., Somers, R., et al. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10033 · Cited by 292
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Katayama, R., Friboulet, L., Koike, S., Lockerman, E. L., Khan, T. M., Gainor, J. F., Iafrate, A. J., Takeuchi, K., Taiji, M., Okuno, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1511 · Cited by 290
Self-citationFusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor
Ma, Z., Hill, D. A., Collins, M. H., Morris, S. W., Sumegi, J., Zhou, M., Zuppan, C., & Bridge, J. A. (2003) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10177 · Cited by 280
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients
Gambacorti Passerini, C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., Messa, C., Guerra, L., Giudici, G., Sala, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt378 · Cited by 279
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Lovly, C. M., McDonald, N. T., Chen, H., Ortiz-Cuaran, S., Heukamp, L. C., Yan, Y., Florin, A., Ozretić, L., Lim, D., Wang, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3667 · Cited by 268
Togashi, Y., Soda, M., Sakata, S., Sugawara, E., Hatano, S., Asaka, R., Nakajima, T., Mano, H., & Takeuchi, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031323 · Cited by 267
Pathobiology of ALK+ anaplastic large-cell lymphoma
Amin, H. M., & Lai, R. (2007) · Blood · doi:10.1182/blood-2007-04-060715 · Cited by 267
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3930 · Cited by 267
Yoshida, T., Oya, Y., Tanaka, K., Shimizu, J., Horio, Y., Kuroda, H., Sakao, Y., Hida, T., & Yatabe, Y. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8732 · Cited by 266
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Heuckmann, J. M., Balke-Want, H., Malchers, F., Peifer, M., Sos, M. L., Koker, M., Meder, L., Lovly, C. M., Heukamp, L. C., Pao, W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3260 · Cited by 261
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 257
Self-citationRenal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum
Debelenko, L. V., Raimondi, S. C., Daw, N., Shivakumar, B. R., Huang, D., Nelson, M., & Bridge, J. A. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.213 · Cited by 244
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
Kodama, T., Hasegawa, M., Takanashi, K., Sakurai, Y., Kondoh, O., & Sakamoto, H. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2578-6 · Cited by 243
Ahn, M.-J., Yang, J., Yu, H., Saka, H., Ramalingam, S., Goto, K., Kim, S.-W., Yang, L., Walding, A., & Oxnard, G. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30246-5 · Cited by 234
Resisting Resistance: Targeted Therapies in Lung Cancer
Lin, J. J., & Shaw, A. T. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.010 · Cited by 232
Self-citationGan, G. N., Weickhardt, A. J., Scheier, B., Doebele, R. C., Gaspar, L. E., Kavanagh, B. D., & Camidge, D. R. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.11.010 · Cited by 221
Lovly, C. M., Heuckmann, J. M., de Stanchina, E., Chen, H., Thomas, R. K., Liang, C., & Pao, W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3879 · Cited by 217
Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., & Riely, G. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt573 · Cited by 206
Self-citationJelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers
Lee, H.-H., Norris, A., Weiss, J. B., & Frasch, M. (2003) · Nature · doi:10.1038/nature01916 · Cited by 194
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Heuckmann, J. M., Hölzel, M., Sos, M. L., Heynck, S., Balke-Want, H., Koker, M., Peifer, M., Weiss, J., Lovly, C. M., Grütter, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1648 · Cited by 191
ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma
De Paepe, P., Baens, M., van Krieken, H., Verhasselt, B., Stul, M., Simons, A., Poppe, B., Laureys, G., Brons, P., Vandenberghe, P., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1050 · Cited by 191
Bilsland, J. G., Wheeldon, A., Mead, A., Znamenskiy, P., Almond, S., Waters, K. A., Thakur, M., Beaumont, V., Bonnert, T. P., Heavens, R., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301446 · Cited by 188
A framework for understanding and targeting residual disease in oncogene-driven solid cancers
Bivona, T. G., & Doebele, R. C. (2016) · Nature Medicine · doi:10.1038/nm.4091 · Cited by 181
Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion
Englund, C., Lorén, C. E., Grabbe, C., Varshney, G. K., Deleuil, F., Hallberg, B., & Palmer, R. H. (2003) · Nature · doi:10.1038/nature01950 · Cited by 179
Colleoni, G. W. B., Bridge, J. A., Garicochea, B., Liu, J., Filippa, D. A., & Ladanyi, M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64945-0 · Cited by 174
Ou, S.-H. I., Azada, M., Hsiang, D. J., Herman, J. M., Kain, T. S., Siwak-Tapp, C., Casey, C., He, J., Ali, S. M., Klempner, S. J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000094 · Cited by 172
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Wilson, F. H., Johannessen, C. M., Piccioni, F., Tamayo, P., Kim, J. W., Van Allen, E. M., Corsello, S. M., Capelletti, M., Calles, A., Butaney, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.005 · Cited by 172
Gainor, J. F., Sherman, C. A., Willoughby, K., Logan, J., Kennedy, E., Brastianos, P. K., Chi, A. S., & Shaw, A. T. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000455 · Cited by 168
Self-citationDebelenko, L. V., Arthur, D. C., Pack, S. D., Helman, L. J., Schrump, D. S., & Tsokos, M. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000088856.49388.ea · Cited by 163
Tanizaki, J., Okamoto, I., Okabe, T., Sakai, K., Tanaka, K., Hayashi, H., Kaneda, H., Takezawa, K., Kuwata, K., Yamaguchi, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0392 · Cited by 163
Sholl, L. M., Weremowicz, S., Gray, S. W., Wong, K.-K., Chirieac, L. R., Lindeman, N. I., & Hornick, J. L. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827db604 · Cited by 162
ALK rearrangement in sickle cell trait‐associated renal medullary carcinoma
Mariño‐Enríquez, A., Ou, W., Weldon, C. B., Fletcher, J. A., & Pérez‐Atayde, A. R. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20839 · Cited by 161
Bazigou, E., Apitz, H., Johansson, J., Lorén, C. E., Hirst, E. M. A., Chen, P.-L., Palmer, R. H., & Salecker, I. (2007) · Cell · doi:10.1016/j.cell.2007.02.024 · Cited by 161
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
WILSON, C. A., Nicholes, K., Bustos, D. J., Lin, E., Song, Q., Stéphan, J.-P., Kirkpatrick, D. S., & Settleman, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2397 · Cited by 155
Tang, S. C., Nguyen, L. N. M., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2013) · International Journal of Cancer · doi:10.1002/ijc.28475 · Cited by 154
Katayama, R., Sakashita, T., Yanagitani, N., Ninomiya, H., Horiike, A., Friboulet, L., Gainor, J. F., Motoi, N., Dobashi, A., Sakata, S., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.12.009 · Cited by 154
Self-citationSugawara, E., Togashi, Y., Kuroda, N., Sakata, S., Hatano, S., Asaka, R., Yuasa, T., Yonese, J., Kitagawa, M., Mano, H., et al. (2012) · Cancer · doi:10.1002/cncr.27391 · Cited by 151
Sukov, W. R., Hodge, J. C., Lohse, C. M., Akre, M. K., Leibovich, B. C., Thompson, R. H., & Cheville, J. C. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.107 · Cited by 151
Reshetnyak, A. V., Murray, P. B., Shi, X., Mo, E. S., Mohanty, J., Tomé, F., Bai, H., Günel, M., Lax, I., & Schlessinger, J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520099112 · Cited by 150
Jazii, F. R. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i44.7104 · Cited by 141
Non‐muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma
Lamant, L., Gascoyne, R. D., Duplantier, M.-M., Armstrong, F., Raghab, A., Chhanabhai, M., Rajcan‐Separovic, E., Raghab, J., Delsol, G., & Espinos, E. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10232 · Cited by 141
Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma
Du, X., Hu, H., Lin, D., Xia, S.-H., Shen, X., Zhang, Y., Luo, M., Feng, Y., Cai, Y., Xu, X., et al. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0159-4 · Cited by 140
Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib
Fujita, S., Masago, K., Katakami, N., & Yatabe, Y. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.105 · Cited by 138
Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen
Zhang, S., Wang, F., Keats, J. A., Zhu, X., Ning, Y., Wardwell, S., Moran, L. E., Mohemmad, Q. K., Anjum, R., Wang, Y., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01239.x · Cited by 134
Marchetti, A., Lorito, A. D., Pace, M. V., Iezzi, M., Felicioni, L., D’Antuono, T., Filice, G., Guetti, L., Mucilli, F., & Buttitta, F. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.111 · Cited by 130
Armstrong, F., Duplantier, M.-M., Trempat, P., Hiéblot, C., Lamant, L., Espinos, E., Racaud‐Sultan, C., Allouche, M., Campo, E., Delsol, G., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207813 · Cited by 129
Ali, S. M., Hensing, T. A., Schrock, A. B., Allen, J. M., Sanford, E. M., Gowen, K. A., Kulkarni, A., He, J., Suh, J. H., Lipson, D., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0497 · Cited by 128
Kim, H. R., Kim, W. S., Choi, Y. J., Choi, C., Rho, J. K., & Lee, J. C. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.08.001 · Cited by 126
Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor
Panagopoulos, I., Nilsson, T., Domanski, H. A., Isaksson, M., Lindblom, P., Mertens, F., & Mandahl, N. (2005) · International Journal of Cancer · doi:10.1002/ijc.21490 · Cited by 126
Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer
Ren, H., Tan, Z., Zhu, X., Crosby, K., Haack, H., Ren, J., Beausoleil, S. A., Moritz, A., Innocenti, G., Rush, A. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3931 · Cited by 124
Aisner, D. L., Nguyen, T. T., Paskulin, D. D., Le, A. T., Haney, J., Schulte, N., Chionh, F. J. M., Hardingham, J. E., Mariadason, J. M., Tebbutt, N. C., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0479-t · Cited by 119
Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas
Hernández, L., Beà, S., Bellosillo, B., Pinyol, M., Falini, B., Carbone, A., Ott, G., Rosenwald, A., Fernández, A., Pulford, K. A. F., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62574-6 · Cited by 115
Takeuchi, K., Soda, M., Togashi, Y., Sugawara, E., Hatano, S., Asaka, R., Okumura, S., Nakagawa, K., Mano, H., & Ishikawa, Y. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0063 · Cited by 114
An Evolutionary Conserved Role for Anaplastic Lymphoma Kinase in Behavioral Responses to Ethanol
Lasek, A. W., Lim, J. P., Kliethermes, C. L., Berger, K. H., Joslyn, G., Brush, G., Xue, L., Robertson, M. A., Moore, M. S., VRANIZAN, K. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022636 · Cited by 112
ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions
Roosbroeck, K. V., Cools, J., Dierickx, D., Thomas, J., Vandenberghe, P., Stul, M. S., Delabie, J., Wolf‐Peeters, C. D., Marynen, P., & Włodarska, I. (2010) · Haematologica · doi:10.3324/haematol.2009.014761 · Cited by 104
Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
Lin, J. J., Kennedy, E., Sequist, L. V. D., Brastianos, P. K., Goodwin, K. E., Stevens, S. E., Wanat, A. C., Stober, L. L., Digumarthy, S. R., Engelman, J. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.126 · Cited by 104
Self-citationCrizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Ceccon, M., Mologni, L., Bisson, W. H., Scapozza, L., & Gambacorti-Passerini, C. B. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0569 · Cited by 99
Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
Murray, P. B., Lax, I., Reshetnyak, A. V., Ligon, G. F., Lillquist, J. S., Natoli, E. J., Shi, X., Folta‐Stogniew, E. J., Günel, M., Alvarado, D., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005916 · Cited by 98
Jung, Y., Kim, P., Jung, Y., Keum, J., Kim, S., Choi, Y. S., Do, I., Lee, J., Choi, S., Kim, S., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21945 · Cited by 95
Toyokawa, G., Seto, T., Takenoyama, M., & Ichinose, Y. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000113 · Cited by 93
Cha, Y. J., Cho, B. C., Kim, H. R., Lee, H., & Shim, H. S. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.097 · Cited by 90
Takegawa, N., Hayashi, H., Iizuka, N., Takahama, T., Ueda, H., Tanaka, K., Takeda, M., & Nakagawa, K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw032 · Cited by 85
Miyawaki, M., Yasuda, H., Tani, T., Hamamoto, J., Arai, D., Ishioka, K., Ohgino, K., Nukaga, S., Hirano, T., Kawada, I., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0211 · Cited by 83
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib
Toyokawa, G., Hirai, F., Inamasu, E., Yoshida, T., Nosaki, K., Takenaka, T., Yamaguchi, M., Seto, T., Takenoyama, M., & Ichinose, Y. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000358 · Cited by 82
Zhou, J., Wang, J., Zeng, Y., Zhang, X., Hu, Q., Zheng, J., Chen, B., Xie, B., & Zhang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.6293 · Cited by 82
Kort, A., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.003 · Cited by 76
Miyamoto, S., Ikushima, S., Ono, R., Awano, N., Kondo, K., Furuhata, Y., Fukumoto, K. J., & Kumasaka, T. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv173 · Cited by 70
Campo, M. J., Al-Halabi, H., Khandekar, M. J., Shaw, A. T., Sequist, L. V. D., & Willers, H. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0508 · Cited by 66
Self-citationJanne, P. A., Shaw, A. T., Camidge, D. R., Giaccone, G., Shreeve, S. M., Tang, Y., Goldberg, Z., Martini, J., Xu, H., James, L. P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.022 · Cited by 58
Self-citationA novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation
Abate, F., Todaro, M., van der Krogt, J.-A., Boi, M., Landra, I., Machiorlatti, R., Tabbò, F., Messana, K., Abele, C., Barreca, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.347 · Cited by 53
Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism
Witek, B., Wakil, A. E., Nord, C., Ahlgren, U., Eriksson, M., Vernersson-Lindahl, E., Helland, Å., Alexeyev, O. A., Hallberg, B., & Palmer, R. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123542 · Cited by 50
Richly, H., Kim, T. M., Schüler, M., Kim, D., Harrison, S. J., Shaw, A. T., Boral, A. L., Yovine, A., & Solomon, B. (2015) · Blood · doi:10.1182/blood-2014-12-617779 · Cited by 46
Self-citationShaw, A. T., Bauer, T. M., Felip, E., Besse, B., James, L. P., Clancy, J. S., Mugundu, G. M., Martini, J., Abbattista, A., & Solomon, B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8018 · Cited by 45
Self-citationGettinger, S. N., Bazhenova, L. A., Salgia, R., Langer, C. J., Gold, K. A., Rosell, R., Shaw, A. T., Weiss, G. J., Narasimhan, N. I., Dorer, D. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8047 · Cited by 42
Self-citationZdżalik-Bielecka, D., Dymek, B., Grygielewicz, P., Gunerka, P., Bujak, A., Lamparska‐Przybysz, M., Wieczorek, M., & Dzwonek, K. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1589-3 · Cited by 41
Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas
Bedwell, C., Rowe, D. W., Moulton, D., Jones, G., Bown, N. P., & Bacon, C. M. (2010) · Haematologica · doi:10.3324/haematol.2010.031484 · Cited by 39
Identification of RANBP2–ALK fusion in ALK positive diffuse large B‐cell lymphoma
Lee, S. E., Kang, S. Y., Takeuchi, K., & Ko, Y. H. (2014) · Hematological Oncology · doi:10.1002/hon.2125 · Cited by 39
dʼAmore, E. S. G., Visco, C., Menin, A., Famengo, B., Bonvini, P., & Lazzari, E. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318287791f · Cited by 38
Gower, A., Hsu, W., Hsu, S.-T., Wang, Y., & Giaccone, G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.11.007 · Cited by 38
Zhang, G., Scarborough, H. A., Kim, J., Rozhok, A. I., Chen, Y. A., Zhang, X., Song, L., Bai, Y., Fang, B., Liu, R. Z., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf5011 · Cited by 30
Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?
Lin, J. J., & Shaw, A. T. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.5891 · Cited by 27
Self-citationDrilon, A. E. D. C., de Braud, F., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Liu, S. V., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct007 · Cited by 23
Self-citationCastellanos, E. H., & Horn, L. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0396 · Cited by 22
Kato, T., Seto, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., Yamamoto, N., Hida, T., Maemondo, M., Nakagawa, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8005 · Cited by 19
Lucena-Araujo, A. R., Moran, J. P., VanderLaan, P. A., Dias-Santagata, D. C., Folch, E. E., Majid, A., Kent, M. S., Gangadharan, S. P., Rangachari, D., Huberman, M. S., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.006 · Cited by 19
Tan, D. S. W., Thomas, M., Kim, D.-W., Szpakowski, S., Urban, P., Mehra, R., Chow, L. Q. M., Sharma, S., Solomon, B., Felip, E., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.11.007 · Cited by 16
Self-citationIadevaia, S., & Ram, P. T. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4920 · Cited by 12
Lemke, G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521923113 · Cited by 8
Cited by
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Duma, N., Santana-Davila, R., & Molina, J. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.013 · Cited by 2,184
Understanding and targeting resistance mechanisms in NSCLC
Rotow, J., & Bivona, T. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.84 · Cited by 972
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30649-1 · Cited by 791
Self-citation
Metadata
- Authors
- Lin, J. J., Riely, G. J., & Shaw, A. T.
- Venue
- Cancer Discovery
- Published
- 2017-02-01
- Volume
- 7
- Issue
- 2
- Pages
- 137-155
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2581592505
- Cited by
- 522
- References
- 170
- FWCI
- 44.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.